source
- Novartis reaffirms $12 billion Avidity acquisition despite $1.9 billion impairment lossNovartis said its $12 billion purchase of Avidity Biosciences remains on track, according to CEO Vas Narasimhan. The comment followed the company's disclosure of a $1.9 billion impairment charge t…
- US Treasury draft COINS rules could sharply limit China biotech partnershipsUS Treasury released a draft set of regulations known as the COINS rule that targets cross-border biotech transactions. The proposal would bar certain US-China deals and tighten oversight of collab…